Neupro (rotigotine transdermal system, from UCB and Schwarz Pharma) patches are being recalled due to the formation of rotigotine crystals in the patches. When the drug crystallizes, less drug is available to be absorbed through the skin. Therefore, the efficacy of the affected product may vary.
Healthcare providers have been advised to not initiate any new patients on Neupro and to begin down-titrating all patients currently using Neupro as per the guidelines in the product label. It is strongly advised that patients do not abruptly discontinue therapy.Neupro will not be available after the end of April 2008.
Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease.
For more information call (800) 477-7877 or visit www.neupro.com.